Folfox-B Study for Patients With Colorectal Liver Metastases

Objective:
* To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease.
Primary Objective:
* To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal.
Secondary Objectives:
* To evaluate the probability of complete response, partial response or stable disease.
* To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery).
* To correlate survival with downstaging and resection based on metastatic colorectal prognostic score.
* To evaluate the disease-free survival and overall survival.
* To evaluate the positron emission tomography response rate.
* To explore correlations of clinical response with telomerase and hTERT expression.